Fig. 7

The benefit of combinatorial therapy in relapsed/refractory NKTL patient. A Top panel, graph depicting the dynamics of EBV DNA copy number in the blood of a relapsed/refractory NKTL patient during treatment with a series of combinatorial therapies. The blue and purple arrows indicate the start time of treatment with the combination of chidamide + sintilimab and chidamide + sintilimab + ruxolitinib, respectively. Middle panel, clinical response to the indicated therapeutic regimens. Bottom panel, representative scans from the patient at baseline and after treatment with the combination of chidamide + sintilimab or chidamide + sintilimab + ruxolitinib. The red arrows indicate lesion locations. B Whole-body PET-CT showing tumor lesions (blue and purple frames) before and after combination treatment with chidamide + sintilimab + ruxolitinib in a relapsed/refractory NKTL patient. C Representative images of H&E staining (upper) and IHC for CD30 (bottom) in an NKTL biopsy before combination treatment with chidamide + sintilimab + ruxolitinib. Scale bars, 50 μm